| Literature DB >> 35806352 |
Dagmara Kociszewska1, Srdjan Vlajkovic1.
Abstract
This article provides a theoretical overview of the association between age-related hearing loss (ARHL), immune system ageing (immunosenescence), and chronic inflammation. ARHL, or presbyacusis, is the most common sensory disability that significantly reduces the quality of life and has a high economic impact. This disorder is linked to genetic risk factors but is also influenced by a lifelong cumulative effect of environmental stressors, such as noise, otological diseases, or ototoxic drugs. Age-related hearing loss and other age-related disorders share common mechanisms which often converge on low-grade chronic inflammation known as "inflammaging". Various stimuli can sustain inflammaging, including pathogens, cell debris, nutrients, and gut microbiota. As a result of ageing, the immune system can become defective, leading to the accumulation of unresolved inflammatory processes in the body. Gut microbiota plays a central role in inflammaging because it can release inflammatory mediators and crosstalk with other organ systems. A proinflammatory gut environment associated with ageing could result in a leaky gut and the translocation of bacterial metabolites and inflammatory mediators to distant organs via the systemic circulation. Here, we postulate that inflammaging, as a result of immunosenescence and gut dysbiosis, accelerates age-related cochlear degeneration, contributing to the development of ARHL. Age-dependent gut dysbiosis was included as a hypothetical link that should receive more attention in future studies.Entities:
Keywords: age-related hearing loss; gut dysbiosis; immunosenescence; inflammation; presbyacusis
Mesh:
Substances:
Year: 2022 PMID: 35806352 PMCID: PMC9266910 DOI: 10.3390/ijms23137348
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
Figure 1The proposed relationship between ageing, gut dysbiosis, and hearing loss. Numbers in arrows indicate a pathway described below. Abbreviations: LPS—lipopolysaccharides; ROS—reactive oxygen species; NF-κB—nuclear factor kappa-light-chain-enhancer of activated B cells; TLR—toll-like receptor; NLRP3—Nod-Like Receptor Pyrin domain-containing protein 3. Ageing is associated with developing gut dysbiosis, and it was proposed that dysbiosis is an underlying cause of age-related morbidities (1) [165,178]. As humans age, inflammaging results from the activation of NF-κB signalling pathways (2) [179]. In addition, the leaky intestinal barrier causes the release of bacterial metabolites into the bloodstream, systemic inflammation, activation of NF-κB (4), and ROS overproduction (32) [180,181,182]. Activation of NF-κB may result in reduced insulin signalling (26) [183,184], which can lead to sterile cochlear inflammation (25) [185,186], and priming of NLRP3 (15) [187,188,189]. Ageing (8) and gut dysbiosis (3) are both associated with dyslipidemia [22,170,190,191,192]. Dyslipidemia can lead to the narrowing of cochlear blood vessels (13) [193,194,195] and lipid raft formation (9) [196,197,198]. Lipid rafts lead to the accumulation of ROS (10) [197] and oxidative stress (OS) (11) [197,199]. OS can activate the NF-κB pathway (24) [200,201] and cause cochlear damage and hearing loss (12) [202,203,204,205,206,207,208]. The cholesterol and lipids obstructing cochlear vessels lead to cochlear ischemia (14), which also contributes to cochlear damage (15) [209,210,211,212,213,214]. Insulin resistance can lead to an electrochemical imbalance in endolymph by decreasing the expression of the sodium-potassium pump NKCC1, reducing the endocochlear potential [215,216,217]. Insulin resistance also decreases nitric oxide production (27) [218,219] resulting in impaired blood flow regulation (28) [188,220], cochlear ischemia (29) and eventually hearing loss (15) [221,222]. Gut dysbiosis can lead to increased levels of circulating lipopolysaccharide (LPS) (5) [223,224,225,226,227,228]. LPS is a bacterial metabolite that can activate NF-κB via toll-like receptors (TLRs) (7) [229,230]. LPS also affects insulin signalling (23) [231,232] and contributes to NLRP3 inflammasome activation [233]. After priming via the NF-κB signalling pathway (15), NLRP3 is activated via ROS (30), resulting in NLRP3 inflammasomes (17). NLRP3 inflammasomes can cause pyroptosis (19) [234], which also produces cochlear damage [32] (21). NLRP3 can also initiate the activation of cochlear macrophages (18) [32], which can increase the BLB permeability and induce sterile cochlear inflammation (20) [22,235,236], leading to hearing loss (22) [22,236].